This study is looking at whether stopping the use of inhaled nitric oxide (iNO) during the initial care of newborns with congenital diaphragmatic hernia (CDH) is effective. CDH is a birth defect where there's a hole in the diaphragm, the muscle that separates the chest from the abdomen. Researchers want to see if de-implementing iNO affects the need for extracorporeal life support (ECLS), a machine that acts as artificial heart and lungs, or the risk of death before leaving the hospital. They are also studying the cost-effectiveness of this approach. You might be able to join if you are a newborn (up to 1 month old) with CDH, including those with other health issues, and have a specific type of hernia called a Bochdalek hernia. The study aims to enroll 600 participants, but its current status is unclear.

Study design

This is a multi-center study where hospitals will first use iNO as usual, then switch to not using it. The timing of this switch will be randomly determined for each hospital.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed from birth through hospital discharge, up to 12 months from birth, to assess outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.